Combining Antipsychotics for Treatment-Resistant Schizophrenia

Guidelines and Recommendations

The National Institute for Health and Care Excellence (NICE) recommends against regular combined antipsychotic medication except for short periods or when augmenting clozapine treatment 2
The World Federation of Societies of Biological Psychiatry guidelines suggest antipsychotic polypharmacy should only be considered in certain individual cases such as treatment-resistant schizophrenia 2
The Finnish Current Care Guideline acknowledges that some patients may benefit from concurrent use of two antipsychotics, specifically noting that combining aripiprazole with another antipsychotic may reduce negative symptoms 2
Most treatment guidelines primarily recommend antipsychotic monotherapy, though they acknowledge specific situations where polypharmacy may be beneficial 1, 2

Aripiprazole added to another antipsychotic (including quetiapine) may help reduce metabolic side effects, weight gain, hyperprolactinemia, and sexual dysfunction 3
The combination of aripiprazole and quetiapine may be useful when a patient has partial response to monotherapy but continues to experience residual symptoms 4
Increased global side-effect burden compared to monotherapy is a potential risk of combining antipsychotics 3
Potential risks of combining antipsychotics include increased risk of Parkinsonian side effects, anticholinergic burden, and cognitive impairment 3

Regular assessment of extrapyramidal symptoms, metabolic parameters, and QTc interval is recommended when combining antipsychotics 3, 5
The American Academy of Family Physicians recommends regular monitoring of overall symptom response and side effects when using antipsychotic combination therapy 5
The decision to combine antipsychotics should be based on careful consideration of the patient's specific symptom profile, previous treatment responses, and side effect vulnerabilities, and regular reassessment is essential to determine if combination therapy remains necessary 3, 6